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Abstract: Epidermolysis bullosa (EB) is a rare disorder characterized
by inherited skin adhesion defects with abnormal disruption of the
epidermal–dermal junction in response to mechanical trauma. Our aim
was to investigate a set of cytokine levels in serum samples from
patients suffering from epidermolysis bullosa simplex (EBS), dys-
trophic epidermolysis bullosa (DEB), and healthy controls (HCs),
exploring their potential correlations with antiskin autoantibody titers
and disease activity. Forty patients afferent to the Dermatological Ward
of Bari City Hospital and 9 HCs were enrolled and subdivided according
to the dystrophic (DEB) and simplex forms (EBS). We found a
significant increase in interleukin (IL)-1b plasmatic levels of DEB
(P¼ 0.0224) and EBS (P¼ 0.0465) patients compared to HCs; IL-6
levels were significantly higher in DEB than in EBS patients
(P¼ 0.0004) or HCs (P¼ 0.0474); IL-2 levels were significantly
increased in DEB compared with EBS (P¼ 0.0428). Plasmatic tumor
necrosis factor-b and interferon-g were higher in DEB patients than in
HCs (P¼ 0.0448 and 0.0229). Conversely, tumor necrosis factor-a was
significantly decreased in DEB (P¼ 0.0034). IL-5 correlated with anti-
BP180 (r¼0.5018, P¼ 0.0338), anti-BP230 (r¼0.6097,
P¼ 0.0122), and anticollagen VII (r¼0.5166, P¼ 0.0405) autoanti-
bodies; interferon-g correlated with anti-BP180 (r¼ 0.9633,Antonio Vitale, MD padula, MD,
Florenzo Iannone, MD
(r¼ 0.5503, P¼ 0.0272). The present study supports that EB might be
considered a systemic inflammatory disease rather than a skin-limited
disorder; clinical disease activity scores could be also integrated by
laboratory data such as IL-6 and IL-12 dosage; biotherapies targeting
specific cytokine networks probably represent a way to go in the future.
(Medicine 94(42):e1528)
Abbreviations: BEBS = Birmingham Epidermolysis Bullosa
Severity, DEB = dystrophic epidermolysis bullosa, EB =
epidermolysis bullosa, EBS = epidermolysis bullosa simplex,
HCs = healthy controls, IFM = immunofluorescence antigen
mapping, IFN = interferon, IIF = immunofluorescence, IL =
interleukin, JEB = junctional epidermolysis bullosa, OD = optical
density, RT = room temperature, TMB = tetramethylbenzidine,
TNF = tumor necrosis factor.
INTRODUCTION
E pidermolysis bullosa (EB) represents a rare group of severeinherited defects known as genodermatoses, and is charac-
terized by abnormalities in skin adhesion. In particular, clinical
phenotype is distinguished by an abnormal skin and mucosa
fragility due to the disruption of epidermal–dermal junction in
response to mechanical trauma, resulting in mutilating scars,
local and systemic infections, syndactyly, and esophageal
strictures.1 According to a recently introduced ‘‘onion skin-
ning’’ approach to classification, EB can be distinguished
taking into consideration the account type, the mode of inheri-
tance, phenotype, immunofluorescence antigen-mapping find-
ings, and mutations.2 Nevertheless, the authors did not change
the previously used names for the major EB types to maintain
continuity with past scientific literature and to prevent any
confusion. In particular, EB types are identified according to the
level in which blisters develop and also include the simplex
form (EBS), with mechanical fragility and blistering confined to
the epidermis; the junctional EB (JEB) consisting of all sub-
types with blisters arising within the lamina lucida of the
dermal–epidermal basement membrane; and the dystrophic
form (DEB), including subtypes with blisters occurring within
the uppermost dermis.
The simplex form derives mainly from mutations of K5
and K14 genes encoding for type I and II keratin intermediate
filaments,3 whereas DEB derives from mutations in the COL7-
A1 gene encoding for type VII collagen—the major component
of anchoring fibrils at the dermal–epidermal junction.4 How-
ever, genotype–phenotype correlations are not always found
and several different phenotypes are reported for DEB regard-ground. In this context, the Birmingham
Severity (BEBS) score is currently
ease activity.5
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Antitype VII collagen and other antiskin autoantibodies
(anti-BP180, anti-BP230) can be detected. Although their
pathogenic role is unclear, their levels have proved to be
significantly correlated with the BEBS score, thus suggesting
that the phenotype severity may rely on autoimmune mechan-
isms.6,7 The potential occurrence of AA-amyloidosis and organ
involvement,8–10 along with previous reported data on cytokine
serum level imbalances,11–13 suggests that moderate to severe
forms of EB should be regarded as systemic inflammatory
disorders rather than local skin diseases.
Therefore, we investigated the levels of a core set of
cytokines in serum samples from EBS and DEB patients,
and healthy controls (HCs), exploring their potential corre-
lations with antiskin autoantibody titers and disease activity.
MATERIALS AND METHODS
Patients
We collected serum samples from a cohort of 40 EB
patients (15 men, 25 women) consecutively seen at the Derma-
tological Ward of Bari City Hospital and diagnosed by clinical
assessment and immunofluorescence antigen mapping (IFM)
and/or transmission electron microscopy. According to the
cross-sectional design of the study, serum samples were col-
lected once during routine follow-up visits. Patients were
divided into 2 groups according to skin cleavage: intraepidermal
blistering diseases (EBS) (15 patients, 7 men and 8 women,
mean age 16 7.3 years), and subepidermal blistering diseases
(DEB) (25 patients, 8 men and 17 women, mean age 33 6.3
years). Samples were also obtained from 9 HCs (1 man, 8
women, mean age 46.77 5.23 years).
The primary aim of the study was to compare cytokine
profiles of EBS patients, DEB patients, and HCs; the secondary
aim was to investigate any potential correlation among cytokines
levels, autoantibody titers, and clinical features. TheBEBS score5
was used to perform clinical assessment of disease severity.
Written informed consent was obtained both from patients and
HCs. The study protocol was reviewed and approved by the
Ethical Committee of the Medical University of Bari.
Cytokine Measurement
Serum cytokine levels of interleukin (IL)-1b, IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12, tumor necrosis factor (TNF)-a,
TNF-b, and interferon (IFN)-g were measured using a human
instant ELISA assay (e BIOSCIENCE, San Diego, CA), accord-
ing to the manufacturer’s instructions. Patients and HCs sera
were added to each well of a microwell plate. Sera were
incubated for 3 hours at room temperature (RT). After washing
to remove any unbound proteins, tetramethylbenzidine (TMB)
substrate was added and incubated for 10 minutes at RT. The
acid solution was then added to each well to terminate the
enzyme reaction and stabilize the color development. The value
in each sample was obtained by comparing the optical density
(OD) of the sample with the OD of the calibrator.
The detection of circulating antiskin autoantibodies was
performed in all samples with an indirect immunofluorescence
(IIF) method (Euroimmun, Lubeck, Germany) and with the
ELISA methods (MBL, Nagoya, Japan). Samples were scored
positive if a fluorescence reaction was observed at 1:10 sample
dilution and autoantibody titers were expressed in units/mL.
Annicchiarico et alStatistical Analysis
Statistical analysis was performed using GraphPad Prism
5 software. Continuous variables are expressed as mean
2 | www.md-journal.comstandard deviation for normally distributed data. Since data
were not homoscedastic, the Kruskal–Wallis test followed by
post-hoc Dunn multiple comparison test was used to compare
the titers of each cytokine assayed by ELISA methods in
patients and in healthy individuals. Correlation analysis was
carried out by using the Spearman rank test. P values <0.05
were considered statistically significant.
RESULTS
Serum Interleukin Levels in EB Patients
Cytokine levels of IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-
10, IL-12, along with TNF-a, TNF-b, and IFN-g, were analyzed
in serum samples from EB patients and 9 HCs. In both EBS and
DEB patients, IL-1b serum levels were found significantly
increased when compared to HCs (P¼ 0.0465 and 0.0224,
respectively), whereas IL-6 levels were significantly higher
in DEB than in EBS patients or HCs (P¼ 0.0004 and
0.0474, respectively). In addition, IL-2 levels were also sig-
nificantly increased in DEB compared to EBS patients
(P¼ 0.0428), whereas serum concentration of TNF-b
(P¼ 0.0448) and IFN-g (P¼ 0.0229) was significantly higher
in DEB patients than in HCs. Conversely, TNF-a was signifi-
cantly decreased in DEB patients (Figure 2C, P¼ 0.0034) than
in HCs. For other cytokines, no difference was detected.
Figure 1 graphically shows significant differences in cytokine
serum levels between EBS and DEB patients, and HCs.
Clinical and Laboratory Correlations
The BEBS score, used to perform clinical assessment of
disease severity, showed a positive correlation with IL-6
(r¼ 0.6941, P¼ 0.029) and IL-12 (r¼ 0.5503, P¼ 0.0272)
serum levels. In addition, IL-5 serum levels inversely correlated
with anti-BP180 (r¼0.5018, P¼ 0.0338), anti-BP230
(r¼0.6097, P¼ 0.0122), and anticollagen VII (r¼0.5166,
P¼ 0.0405) autoantibody titers. Furthermore, IFN-g levels were
directly correlated with anti-BP180 (r¼ 0.9633, P< 0.0001),
anti-BP230 (r¼ 0.9071, P< 0.0001), and anticollagen VII
(r¼ 0.8619, P¼ 0.0045) autoantibody titers.
Finally, serum levels of IL-10 were found to be correlated
with anticollagen VII (r¼ 0.48, P¼ 0.037) and with anti-BP230
titer (r¼ 0.45, P¼ 0.05). Table 1 provides more information
about autoantibodies detected in the present study. Figure 2
shows the main correlations among cytokine serum levels,
autoantibody titers, and BEBS score.
DISCUSSION
Our cross-sectional study was aimed at searching for a
peculiar cytokine pattern in EB patients and exploring the
potential associations among cytokine profiles, autoantibody
serum levels, and disease activity, evaluated by the BEBS
score. In particular, we found increased IL-1b serum levels in
EBS and DEB patients, whereas IL-2 was higher in DEB than
in EBS patients, and IL-6 was higher in DEB patients than in
both EBS patients and HCs. In addition, TNF-b and INF-g
levels were higher in patients affected by DEB, whereas
TNF-a was significantly lower in such patients. Furthermore,
IL-6 and IL-12 were positively correlated with the BEBS
activity score, whereas IFN-g and IL-5 were correlated with
skin autoantibodies in a positive and negative manner,
Medicine  Volume 94, Number 42, October 2015respectively.
These results strengthen that systemic involvement is
hidden below mucocutaneous manifestations in EB patients.
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with a more severe phenotype suggested a potential multisystem
involvement in such patients. In particular, IL-1 has been
referred to be responsible for abnormal fat metabolism, cardi-
ovascular complications, renal sclerosis, weight loss, and
systemic amyloidosis in most severe EB cases.8–10,14–16 In
addition, IL-1b signaling was found constitutively activated
in keratinocytes from EBS patients, resulting in activation of the
JNK stress pathway and overexpression of IL-1b in a positive
feedback loop.11 In line with these findings, our results support
the role of IL-1b in inducing systemic involvement in
EB patients.
According to previously reported data,12 we found high IL-
6 serum levels in DEB patients. This cytokine, mainly produced
by activated macrophages, monocytes, antigen-presenting cells,
and lymphocytes, is capable of promoting Th17 cell and
monocyte differentiation, and also inducing the production of
acute-phase proteins, thus playing a key role in the switch from
innate to acquired immunity.17 Noteworthy, IL-6 upregulation
has been previously identified in DEB patients complaining of a
more severe phenotype,18 thus supporting our findings showing
a correlation of IL-6 (and IL-12) with the BEBS score. Note-
worthy, since BEBS score is not adjusted for patients’ age, IL-6
and IL-12 dosage could provide more details on disease sever-
ity, especially among children.13 However, since IL-6 levels
were found significantly higher in DEB than in EBS patients,
the role of IL-6 on disease activity evaluation could be more
important in the former group. In addition, IL-6 has previously
proved to be significantly upregulated at the mRNA level in
skin obtained from K5/ mouse models.19 Consequently,
FIGURE 1. Significant differences in cytokine serum levels betw
epidermolysis bullosa (DEB), and healthy controls (HCs). Data (p
P values were obtained from Dunn multiple comparison test afteboth the role of IL-6 on pathogenesis and the possible relation
with disease activity in EBS patients should be investigated on a
larger number of patients.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.To date, in vitro production of IL-2 from in vitro periph-
eral blood mononuclear cells (PBMCs) has been previously
reported to be very low in DEB patients,20 and a diminished
number of IL-2 receptors were also found in patients
with severe forms of EB.21 Noteworthy, in the present study,
IL-2 was found to be significantly increased in DEB than in
EBS patients, thus making necessary further studies to better
understand the role of IL-2 in such patients. In any case, the
different IL-2 expression in DEB and EBS patients, and the
higher IL-6 levels found in DEB than in EBS patients probably
reflect diverse pathogenetic mechanisms supported by the
different genetic defects.
Interestingly, we found decreased TNF-a serum levels in
DEB patients compared to HCs. According to previous pub-
lished data, mesenchymal stem cells preconditioning with TNF-
a showed to improve transplantation functional utility in reces-
sive DEB.22 In addition, collagen VII gene expression was
reported to be increased by TNF-a through TGF-b signaling in
HaCaT keratinocytes.23 In this regard, reduced TNF-a levels in
EB patients could have a role in inducing a decreased or
aberrant collagen VII production.
A significant increase in IFN-g levels was also found in our
DEB patients. In this context, IFN-g proved to mightily activate
the keratin K15 promoter in human epidermal keratinocytes,24
whereas IFN-g blockers have been successfully proposed as
possible pharmacological approach for DEB patients.25 Nota-
bly, in our DEB patients, IFN-g positively correlated with anti-
BP180, anti-BP230, and anticollagen VII autoantibody titers,
pointing out its role in immunomodulation and regulation of
adaptive immune response. Furthermore, collagen VII and
patients with epidermolysis bullosa simplex (EBS), dystrophic
L) are expressed as means; since data were not homoscedastic,
uskal–Wallis test.BP230 autoantibody titers negatively correlated with IL-5,
indicated as promoter of CD4þCD25þ T-regulatory cells that
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could be the consequence of genetic defects and skin blistering
rather than the keystone of etiopathogenetic mechanisms.
Nevertheless, although further studies on larger populations
are mandatory to better establish the real role for each cytokine,
in the present study, IFN-g and IL-5 were found related to
antibody titers, thus suggesting their pathogenetic role in indu-
cing deregulation of adaptive immune system in such patients.
However, looking further into the future, our findings encou-
FIGURE 2. Main significant correlations identified between cytoki
VII) titers, and Birmingham Epidermolysis Bullosa Severity (BEBS)
means; r and P values were obtained from Spearman test.rage the employment of biologic agents targeting specific
cytokine networks. This alternative therapeutic approach could
be useful to counteract both skin manifestations and systemic
4 | www.md-journal.comlong-term complications such as AA-amyloidosis, thus avoid-
ing life-threatening consequences and improving quality of life.
Nevertheless, nonhealing blisters may ease infections in EB
patients, and patients treated with biologic therapy are at an
increased risk of developing infections. For these reasons, anti-
IL-1 agents could represent an optimal opportunity because of
their lower infectious risk than other biologics.27 Furthermore,
wound healing might close potential opened doors to infections.
In conclusion, the imbalance of several cytokines high-
serum levels, autoantibody (anti-BP180, anti-BP230, anticollagen
re in overall EB patients enrolled. Data (pg/mL) are expressed aslighted in the present study confirms that EB is a systemic
inflammatory disease rather than a skin-limited disorder. In
addition, IL-6 and IL-12 dosage may represent a useful and not
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.








Mean value 43.84 35.75 20.22
Standard error 9.64 7.67 4.99
Standard deviation 40.91 30.66 19.96
Median value 35.25 26.9 13.65
Variance 1673.48 940.31 398.22
Minimal value 2.7 3.3 1.1
Maximal value 161 120.7 76.7
Medicine  Volume 94, Number 42, October 2015invasively laboratory tool, in addition to the currently used
severity score aimed at establishing disease activity. Whether or
not some of these cytokines may be a potential target of new
biotherapies needs further investigations. This might open new
avenues in the treatment of a complex disease often leading to
life-threatening complications.
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